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ABSTRACT 
Viruses are ubiquitous and are also the pathogenic agents that are most commonly associated with neoplastic 
transformation of cells of several organs in human beings – thereby causing cancer of  epithelial cells (carcinomas) or 
cancer of mesenchymal cells (leukemias, lymphomas and sarcomas) depending on the type and location of the 
infected host cell. This review highlights the six major groups of viruses that have established aetiological association 
with cancer in human populations. The epidemiology and the processes through which these pathogens cause 
malignant transformation of the infected host cells are discussed – with particular emphasis on the evolving and 
changing natures of the diseases as they parallel changes in human behaviours. Also discussed is a brief overview of 
the current understanding of molecular pathology as they emerge with the advent of new technological capabilities 
for studying these processes at subcellular (genomic) levels. 
 
INTRODUCTION 
Viruses have notoriety for causing acute 
epidemic infections that may result in pandemics 
and global crisis within a short period of time. 
But also of  an ever increasing need for attention 
due to the public health risk they constitute, are 
endemic diseases of viral origin and the 
associated malignancies.  Viruses cause chronic 
infections that are endemic in many communities 
and such chronic infections have been shown to 
have aetiological associations with certain 
malignant disease processes that are also of 
endemic proportions in the affected 
communities. Considering the ubiquity of viruses 
and the high prevalence of viral infections world-
wide, viruses are probably second only to 
tobacco abuse as the most common risk factor for 
developing cancer.  In some cases, the 
development of cancer is directly related to the 
activities of the virus. In other cases, the virus 
remains dormant in host cells (carrier state) until 
factors such as immunosuppression and/or 
infection with other oncogenic viruses activates 
the oncogenic potentials of the virus in the 
carrier. This review highlights the interplay 
between environmental factors, host factors and 
viral factors that influence the oncogenic 
transformation of virus-infected host cells.  
 
1. EPSTEIN BARR VIRUS 
 
1:1 Epstein Barr Virus (EBV) Infection and The 
Immune System. 
 
Epstein Barr Virus (EBV) is a gamma herpesvirus 
that was first discovered in 1964 in SubSahara 
Africa by Epstein, Achong and Barr when they 
observed and reported the presence of herpes-
virus-like particles in electron micrographs of 
cultured Burkitt lymphoma (Burkitt’s 
Lymphoma) cells (1).  Shortly thereafter, higher 
titers of antibody to EBV antigens were reported 
in Burkitt’s Lymphoma patients (2), infectious  
mononucleosis and undifferentiated 
nasopharyngeal cancer (3,4).  Since then, EBV has 
been shown to be an ubiquitous virus and the 
putative agent for an array of neoplastic 
lymphoproliferative disorders that include 
Hodgkin’s disease, non-Hodgkin’s B-cell 
lymphomas, immunosuppression-associated 
lymphomas, some T-cell lymphomas; and a 
subset of gastric adenocarcinoma.  All these 
tumours have been shown to contain EBV 
genome and EBV-coded latent genes which play 
active roles in the malignant transformation of 
infected cells.  
 
EBV is a linear double-stranded DNA gamma-
herpesvirus with global presence.  It infects about 
95% of adult populations in every part of the 
world and has a life-long persistence in infected 
individuals.  The primary infection may be 
asymptomatic and occur early in life or it may 
occur later during pubertal years or adulthood as 
infectious mononucleosis (5,6).  Although the 
virus can infect epithelial cells, T-lymphocytes 
and B-lymphocytes, the latter are the preferred 
target cells (7).  EBV is orally transmitted and the 
oropharynx is the primary site of infection and 
also the site for virus replication; hence, the 
spread of the virus through the saliva of infected 
persons (8,9). During the primary infection of B-
cells, there is an initial short-lived but critical 
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burst of lytic viral replication which enhances 
spread of the virus to other cells and culminates 
in transformation of the host cells and 
establishment of non-productive latent infection 
(7).  In the latency state, instead of replicating in 
the infected cells, the virus produces a variety of 
latent genes and proteins that mediate adaption 
of the virus to the host cells physiology to ensure 
survival of the virus, persistence of infection and 
avoidance of host immune surveillance 
mechanisms. 
 
Inhibition or removal of the immune T-cells in in-
vitro systems results in spontaneous 
transformation of resting EBV-infected B-cells 
into indefinitely proliferating lymphoblastoid cell 
lines (LCLs) that express high levels of B-cell 
activation markers (CD23, CD30, CD39 and 
CD70) (10); and contain multiple copies of the 
viral episome; nine latent proteins comprised of 
six EBV nuclear antigens (EBNAs) and three 
latent membrane proteins (LMPs).  The nuclear 
antigens consist of EBNAs 1, 2, 3A, 3B, 3C and 
LP; and the LMPs include LMP1, 2A and 2B (11).  
EBERs 1 and 2 are small non-polyadenylated 
(non-coding) EBV RNAs that are also abundantly 
expressed in latently infected cells. Although 
they are not essential for transformation of EBV-
infected cells into immortalized LCLs (6); they 
are useful as markers of latent EBV infections (5).  
Also identified in latently infected cells and also 
in EBV-associated tumours, are the BARTs 
(Bamh1 A rightward transcripts).  These are 
believed to play some role in enhancing virus 
persistency through yet to be defined 
mechanism(s) (12). It appears viral persistence in 
host cells is enhanced and ensured through a 
host of mechanisms including limited expression 
of viral antigens during latency (> 80 antigens 
expressed during lytic replication compared with 
9 in latency), reduced copy member of the 
expressed viral antigens, production of virus 
encoded RNAs (EBERs) which may protect EBV-
infected cells from apoptosis, and use of putative 
latency program (latency 0) in which no 
detectable latency gene is expressed in the 
infected cells – thus rendering such infected cells 
invisible to the host’s immune surveillance 
machinery (13). 
 
Under normal circumstances, latent EBV 
infection is kept in check and precluded from 
actively spreading to infect and immortalize 
other host cells by a combination of T and B cell 
responses to the detectable EBV latent antigens. 
Abrogation or suppression of these host immune 
responses may tilt the balance in favor of active 
viral replication and so facilitate the development 
of EBV associated malignancies.  Such situations 
may be iatrogenic immunosuppression as in 
transplant patients or due to co-infection by other 
pathogens such as Human Immunodedeficiency 
Virus (HIV) and Plasmodium  falciparum, or local 
immune suppression resulting from changes in 
the tissue microenvironment (13).   
 
1:2 EBV and Burkitt’s Lymphomas 
 
The discovery of EBV resulted from a striking 
observation that Burkitt’s lymphoma was 
endemic in the SubSahara African region that 
was also holoendemic for Plasmodium  falciparum 
infection (1).  In that region, Burkitt’s Lymphoma 
is 50 times more common compared with other 
regions with sporadic cases of the tumour.  Also, 
in endemic Burkitt’s Lymphoma, EBV positivity 
in tumour cells is 100% compared to only 15-20% 
in sporadic cases (11,14).  Burkitt’s lymphoma is 
also common in HIV-infected patients – about 
40% of AIDS-related Burkitt’s lymphoma has 
been   associated with EBV (15). 
 
A characteristic chromosomal abnormality 
consistently present in all cases of Burkitt’s 
Lymphoma is translocation of the region of c-myc 
proto-oncogene from the long arm of 
chromosome 8 (8q24) to the region of the 
immunoglobulin heavy chain gene on 
chromosome 14; or less commonly to the regions 
of the immunoglobulin light chain genes on 
chromosomes 2 or 22.  This results in 
dysregulation of the c-myc oncogene with 
consequent activation of pathways that favor 
malignant proliferation of the infected cells. 
(16,17). EBNA1 which is the only EBV protein 
consistently detected in Burkitt’s Lymphoma 
interact with the dysregulated c-myc to alter B-
cell growth and so transforms the cell into a state 
of continuous proliferation (5). 
 
Malaria infection causes polyclonal activation of 
B-lymphocytes and general immunosuppression 
including downregulation of EBV specific 
cellular T lymphocyte (CTL) response.  These 
result in up to five-fold increase in the number of 
circulating EBV-infected B-cells during acute 
malaria infection. (18). In children with Burkitt’s 
Lymphoma, CTL response against EBNA1 is 
significantly decreased while CTL responses 
against other EBV antigens are unaffected (19)  
 
1:3 EBV and Hodgkin’s Lymphoma 
 
Hodgkin’s lymphoma is the most common EBV-
associated lymphoma in the western world with 
3 
 
18-50% EBV positivity rate in Hodgkin’s 
lymphomas (20-22).  In developing countries, the 
frequency of EBV associated Hodgkin’s 
lymphoma is (much) higher and may be as high 
as 100% with EBV RNA and/or antigens being 
detected in virtually all cases in some published 
series, depending on the sensitivity of the assay 
employed (23,24). 
 
EBV having a possible casual role in the 
pathogenesis of Hodgkin’s lymphoma was 
deduced from the observation of two to three 
fold increased risk for developing Hodgkin’s 
lymphoma by patients with history of infectious 
mononucleosis (25). The first concrete evidence 
that showed EBV as a causative agent for 
Hodgkin’s lymphomas was the detection of 
higher EBV antibodies titers in Hodgkin’s 
lymphoma patients compared with other 
lymphoma patients (26), and observations that 
elevation of EBV antibodies titers in Hodgkin’s 
lymphoma patients occurred several years before 
the development of the tumour (27). 
 
The presence of EBV DNA in Hodgkin’s 
lymphoma tissue samples was first  
demonstrated in 1987 with the use of in-situ 
hybridization probe.  Since then, several studies 
have confirmed the presence of EBV DNA, RNAs 
and antigens in tissue samples of Hodgkin’s 
lymphoma – using improved in-situ 
hybridization and immunohistochemical 
methods (5). Type 1 EBV is the usually detected 
“variant” but type 2 virus has also been reported 
in Hodgkin’s lymphoma that develops in clinical 
settings of immunodeficiency.  Transcripts 
analysis and hybridization studies have also 
shown clonality for EBV in Hodgkin’s lymphoma 
tissues samples – thus confirming those tumours 
resulted from clonal expansion of single EBV–
infected cells (28).  EBV is usually associated with 
the mixed cellularity histopathologic form of 
Hodgkin’s lymphoma and is more common in 
males, and also in pediatric patients and older 
patients (>55 years of age) (29,30). 
 
Immunohistochemical studies and 
transcriptional analysis of Hodgkin’s lymphoma 
tissue samples have shown EBV infected 
Hodgkin’s lymphoma cells (Reed-Sternberg’s 
cells) contain high levels of the EBV latent 
antigen LMP1 in the absence of EBNA2 (31-33). 
In the Hodgkin’s lymphoma cells, LMP1 causes 
nuclear activation of NF-Kappa B, decrease the 
cell’s susceptibility to apoptosis, and upregulate 
the production of immunosuppressive cytokines 
like IL-10, IL-13 and TAF-B (6,34-36).  Thus EBVs 
LMP1 latent antigen appears to stimulate and 
enhance the clonal expansion of Reed-Sternberg’s 
cells by dysregulating the cell-cycle/apoptosis 
mechanisms and also by activating the cells to 
produce substances that have 
immunosuppressive effects on the 
microenvironment – thereby allowing the cells to 
escape the host’s immune mechanisms (13). 
 
1:4 EBV and Immunosuppression – Related 
Lymphoproliferative Diseases 
 
EBV is also implicated as the causative agent in a 
number of lymphoproliferative disorders that 
occur in the clinical settings of 
immunosuppression.  These include:  post-
transplant lymphoproliferative disorders 
(PTLDs), inherited immunodeficiency associated 
lymphoproliferative syndromes and HIV 
infection – related lymphomas.  In these disease 
conditions, immunosuppressions results in 
unabated chronic antigenic stimulation (in the 
transplanted organ and also in the host patient’s 
own tissue), enhance the activation and 
transformation of cells with latent EBV infection 
and allows the virus to escape from EBV-specific 
immune control mechanisms. These events 
combined in due course culminate in aggressive 
and uncontrolled proliferation of transformed 
EBV-infected cells.  
 
EBV-associated HIV-related nonHodgkin’s 
lymphomas include primary CNS lymphoma, 
Human herpes virus 8 (HHV8)-positive primary 
effusion lymphoma and it’s solid variant, and 
plasmablastic lymphoma. Other EBV-associated 
lymphomas that may also occur in HIV-infected 
patients are diffuse large cell lymphomas with 
immunoblastic features and Burkitt’s lymphoma 
(37). About 40% of AIDS associated Burkitt 
lymphomas are positive for EBV (15). In PTLDs 
and HIV-associated diffuse large cell 
lymphomas, majority of the cases are EBV-
positive and expresses all the latent antigens 
(latency III) (6). 
 
Primary effusion lymphoma (PEL) is a tumour 
that occurs frequently in HIV-infected patients 
and is very rare in immunocompetent 
individuals. These tumours appear to develop as 
a result of co-infection by EBV and Kaposi’s 
sarcoma herpes virus - HHV8 (also a gamma 
herpes virus) (20). Both PEL and EBV positive 
HIV-related Burkitt’s lymphoma express EBNA1 
as the only EBV protein and both are also 
characterized by upregulation of c-myc oncogene 
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to stimulate cell proliferation and increase 
resistance to apoptosis (38-40). 
 
1:5 Nasopharyngeal Carcinoma 
 
Undifferentiated nasopharyngeal carcinoma 
(UNPC; WHO type III) has a consistent global 
association with EBV.  This tumour has a rather 
high incidence in Southeast Asia particularly in 
Southeast China and neighboring Hong Kong 
with a peak incidence of 20-30 cases per 100,000.- 
and is the eighth leading cause of death in China 
(41-43).  A relationship between EBV and UNPC 
was first suggested based on presence of high 
titers of EBV antibodies in UNPC patients.  That 
was followed with in-situ demonstration of EBV 
DNA and EBNA proteins in the tumour cells (4). 
Also, EBV genomes in UNPC tumour cells have 
been shown to be monoclonal, suggesting the 
tumour results from clonal proliferation of cells 
with latent EBV-infection (44). 
 
Irrespective of geographic location, UNPC is 
invariably positive for EBV with a 100% 
positivity rate (45-47). EBNA1 and EBERs are 
detected in 100% of cases and LMP1 in up to 65% 
cases depending on the sensitivity of the assay 
(48,49).  Elevation of IgA titers against EBV 
antigens may occur several years before 
development of UNPC. The antibody titer also 
correlates with tumour burden, remission and 
recurrence (50,51)).  Therefore, EBV-specific 
serology (titers of IgA antibodies to EBV capsid 
antigen and early antigens) is now employed as 
invaluable tool in the management of UNPC for 





    Figure 1 
 
A. Hematoxylin and Eosin-stained tissue section micrograph of EBV-associated  
nasopharyngeal undifferentiated carcinoma. 




In addition to EBV infection, other non-viral 
factors contribute to the development of UNPC 
in affected individuals.  These include genetic 
predisposition, consumption of salted fish and 
meats containing the preservative nitrosamine 
and a prolonged exposure to domestic wood 
cooking (for at least 10 years) (43,50). The report 
of high incidence rates of this tumour  in 
individuals of chinese descent (especially 
Cantonese males)  that are residents in other 
parts of the world that are not endemic for EBV 
infection, suggests genetic predisposition as a key 
underlying factor for the development of EBV-
associated nasopharyngeal carcinoma (5). 
 
1:6 EBV and T-cell lymphomas 
 
Although B-cells are the preferred cells for EBV 
infection, the virus can also infect CD4+ and 
CD8+ T-cells and Natural Killer (NK) cells (54).  
A number of EBV-associated T-cell/Natural 
Killer cells lymphoproliferative disorder have 
been reported; the most common of these is 
sinus-nasal T-cell nonHodgkins lymphomas 
(SNTL).  SNTL have been reported in Asia, 
Europe, North and South America and do not 
appear to have distinctive geographical or racial 
distribution (55).  These tumours 
characteristically express NK markers, may lack 
T-cell antigens and do not express T-cell receptor 
gene re-arrangements. In in-vitro experimental 
settings, T-cells are refractory to EBV infection; 
therefore the exact mechanism(s) of how EBV 
infects T-cells and participate in development of 
T/NK cells lymphoma is still an enigma (15). 
 
Since most EBV-associated T-cell lymphomas 
develop in the context of chronic active EBV 
infection (of B-cells), there are suggestions that 
EBV-associated T-cell oncogenesis may be a 
result of proliferating cytotoxic T-cells trying to 
kill the EBV infected cells.  This assertion is  
supported by the fact that most EBV-associated 
T-cell lymphomas have cytotoxic phenotype 
(positive expression of granzyme B and T-cell 
intracytoplasmic antigen-1 [TIA1]). Type II 
latency (expression of EBNA1 and LMP 1, 2A 
and 2B) is characteristic but interestingly, EBV is 
detected only in a fraction (5-50%) of tumour 
cells -  implying EBV infection may have 
occurred after development of the tumour (56).  
EBV-infected B cells with type III latency are 
frequently detected in T-cell lymphomas and 
may contribute to the neoplastic T-cells through 
secretion of tumour-enhancing cytokines or 
direct stimulatory interactions with the T-cells 
(6).  
 
1:7 EBV and Gastric Carcinoma 
 
EBV-associated gastric carcinoma is defined by 
the presence of EBV in the tumour cells – 
irrespective of the histologic appearance of the 
tumour.  In 1990, Burke et al using PCR-based 
detection method, reported the presence of EBV 
genome in a group of gastric carcinoma 
characterized by a lymphoepithelioma-like 
histologic appearance (57).  Subsequent studies 
with in-situ hybridization in the 1990s reported 
the abundant presence of monoclonal EBV 
(positive EBER signals) in a subset of gastric 
adenocarcinoma including those that lack the 
lymphoepithelioma-like histomorphology.  The 
studies also showed the abundant presence of 
EBER in virtually all tumour cells; and none in 
surrounding benign epithelial cells (58-61). Also 
suggesting possible etiological role for EBV in 
these tumours is the presence of elevated titers of 
EBV prior to the diagnosis of EBV-associated 
gastric carcinoma (62). According to pooled 
(meta-analysis) data from America, Asia and 
Europe, about 10% of gastric carcinomas are 
associated with EBV (63).  
 
In-situ hybridization has also shown the virus 
(EBER signals) to be present in the tumour cells 
at all stages – from pre-invasive intramucosal to 
invasive stage. Genomic terminal repeat studies 
have confirmed the monoclonality of the EBV in 
the tumour cells and  also showed EBV infection 
in the tumour cells is latent (with no active viral 
replication); and that the virus exist in the 
tumour cells in unintegrated (episomal) forms 
(59,61,64).  These data taken together show EBV 
infection and its role in neoplastic transformation 
of gastric epithelial cells occur early in the 
premalignant stage. 
 
Unlike EBV-associated undifferentiated 
nasopharyngeal carcinoma which is 
characterized by intense stromal lymphocytic 
infiltrate, the overwhelming majority (about 80%) 
of EBV-associated gastric carcinoma has notably 
less but varying degrees of lymphocytic infiltrate 
– i.e. akin to what obtains with regular gastric 
carcinomas.  However, irrespective of their 
histomorphologic appearance, all EBV-associated 
gastric carcinomas share the following 
clinicopathologic features:  They occur 
predominantly in males, relatively younger 
patients and unlike Helicobacter pylori-associated 
carcinomas, tend to be localized to proximal 
regions (cardia and body) of the stomach.  
Compared with regular gastric carcinomas, EBV-
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associated tumours also tend to have relatively 
better prognosis with lower rate of lymph node 
metastasis (65,66). 
 
Exactly how EBV infects gastric mucosa epithelial 
cells and establishes latency therein is still a 
matter of speculation.  However, in-situ 
hybridization studies have shown EBV infected 
epithelial cells in the fundic glands to be the 
likely nidus of the viral infection that eventually 
results in malignant transformation of the 
epithelial cells.  In the infected cells, EBV through 
its oncoproteins (LMP1 and LMP2A), causes 
global non-random aberrant (CρG island) 
methylation of the promoter regions of several 
oncogenes such as p14, p16, p73, CDH1 and 
PTEN (57,60,67).  Carcinoma with 
Lymphoepithelima-like histologic appearance 
has been reported in other organs including liver, 
oral cavity and breast, but EBV has not been 
conclusively associated with any of these 
tumours. 
  
2. CHRONIC VIRAL HEPATITIS AND 
HEPATOCELLULAR CARCINOMA 
 
2:1 Viral Hepatitis and Hepatocellular 
Carcinoma  
 
Hepatocellular carcinoma is the fifth most 
common cancer and the third leading cause of 
cancer related deaths worldwide (68).  The 
incidence of hepatocellular carcinoma is rising in 
the western world. In the United States of 
America, both the incidence of hepatocellular 
carcinoma and rate of cancer-related death due to 
hepatocellular carcinoma is on the rise, even 
though the overall rate of cancer deaths is 
declining. This paradoxical situation has been 
attributed to an increase in HBV related 
hepatocellular carcinoma among immigrants 
from endemic countries and also partly to an 
increase in the incidence of hepatitis C infection 
in the American populace (69)  in which up to 
two thirds of hepatocellular carcinoma  are 
related to chronic HCV infection (70) 
 
Infection with hepatitis B virus (HBV) and 
hepatitis C virus (HCV) is the number one risk 
factor for hepatocellular carcinoma worldwide, 
with these viral infections accounting for over 
80% of all hepatocellular carcinoma cases 
globally (71).  The remaining 20% of 
hepatocellular carcinoma  is attributed to other 
risk factors such as alcohol consumption, 
aflatoxin B1, and other chronic liver disease such 
as non-alcoholic fatty liver disease, and inherited 
metabolic diseases (hemochromatosis  and alpha 
one antitrypsin deficiency) (69). 
 
 
2:2:1 Hepatitis B Virus and Hepatocellular 
Carcinoma   
 
The association of hepatocellular carcinoma  with 
chronic hepatitis B infection was first noted in 
1970 and confirmed by subsequent studies in the 
following two decades leading to the established 
and now undisputed fact that more than 80% of 
patients with hepatocellular carcinoma  reside in 
high incidence areas (East Asia and Sub-Saharan 
Africa) where more than 80 % of patients with 
hepatocellular carcinoma  were seropositive 
hepatitis B surface antigen (HBsAg), compared 
with 10-15% positive rate in control populations.  
Also, serologic evidence of active or previous 
HBV infection evidenced by positive hepatitis B 
core antigen (serum positivity) has been reported 
in more than 90% cases of hepatocellular 
carcinoma (69).  A definite aetiological 
association of HBV with hepatocellular 
carcinoma was reported in 1981 by Beasley et al 
(72) following their large prospective cohort 
study of 22,707 male municipal workers in 
Taiwan between 1975 and 1980.  3,454 (15.2%) 
were seropositive for HBsAg with 40 of them 
dying from hepatocellular carcinoma  compared 
with only one hepatocellular carcinoma -related 
death among the 19,253 HBsAg seronegative 
participants.  The incidence of hepatocellular 
carcinoma  among the HBsAg carriers was 1,158 
per 100,000 compared with 5/100,000 in their 
seronegative counterparts; and a calculated 
relative risk of 223 for hepatocellular carcinoma 
developing in seropositive individuals.  A more 
recent and larger prospective cohort study 
involving 90,000 participants and including 
11,000 HBsAg positive patients followed over a 
period 8 years, showed that hepatitis B virus 
infected patients have 18.8 and 33.2 risk for 
hepatocellular carcinoma  in men and women 
respectively (73).  These studies and others have 
proven unequivocally, the association between 
hepatitis B virus infection and hepatocellular 
carcinoma. 
 
Another direct evidence of causative linkage 
between hepatitis B infection and hepatocellular 
carcinoma is the relationship between level of 
serum HBV DNA (marker of HBV replication) 
and the risk of hepatocellular carcinoma.  Several 
studies have shown that there is a direct 
relationship between serum levels of HBV DNA 
and risk of hepatocellular carcinoma; with 
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elevated baseline serum level of HBV DNA 
greater than 10,000 copies per mL (approximately 
2,000 IU/mL) being a strong predictor of 
subsequent development of hepatocellular 
carcinoma.  This association has also been shown 
to be independent of serum Hepatitis B e antigen 
(HBeAg) status, serum aminotransferases levels, 
or the presence of cirrhosis (74,75). Serum 
positivity for HBeAg was previously considered 
to be a risk factor for development of 
hepatocellular carcinoma.  However, subsequent 
studies have not shown it to be an independent 
predictor of development of hepatocellular 
carcinoma.  It is now thought it effects may be 
dependent on the underlying levels of HBV DNA 
in the serum as well as the genotype of the HBV 
involved (74,76).  There is a definite association 
between certain types of HBV genotypes and 
higher risk and rate of hepatocellular carcinoma.  
Of the eight known HBV genotypes (A-H), based 
on genomic sequence divergence, HBV genotype 
C infected patients are generally believed to have 
increased risk of developing hepatocellular 
carcinoma  compared with patients infected with 
other genotypes (75,77).  HBV genotype C has 
also been associated with poorer surgical 
outcomes and higher hepatocellular carcinoma 
recurrence rate following surgical resection of the 
primary tumour. This is probably due to the 
higher pathogenicity of this genotype – as the 
patients tend to have more active disease in the 
residual liver (78). However, a few studies have 
also shown that in some populations, genotype B 
or even genotype F may be associated with 
higher risk for developing hepatocellular 
carcinoma (79)  
 
2:2:2 Hepatits B Virus and Viral 
Hepatocarcinogenesis 
 
Hepatitis B virus is a double stranded DNA virus 
that belongs to the Hepadnavirus family. The 
virion has a diameter of 42 nanometer (nm) and 
is composed of an outer envelope formed by 
hepatitis B surface antigen surrounding an inner 
nucleocapsid, the hepatitis core antigen, which 
contains the viral genome and polymerase (68).  
The process through which HBV causes 
oncogenic transformation of infected hepatocytes 
is yet to be fully elucidated. It involves a complex 
multistep process involving the activation of 
cellular oncogenes, the inactivation of tumour 
suppression genes, and dysregulation of multiple 
signal transduction pathways that are critical to 
control of cell proliferation and viability, 
apoptosis, and cellular DNA repair mechanisms.   
 
Although, HBV can replicate on its own without 
integrating into the HBV DNA, its integration 
into the host genome does allow for persistence 
of the viral genome within the host cells (80).  It 
appears HBV causes hepatocellular carcinoma 
principally through the integration of its DNA 
into the host genome.  Integration of HBV into 
the genome as evidenced by the presence of HBV 
DNA in tumour cells has been found in about 
80% of HBV related hepatocellular carcinoma.  
HBV DNA has also been found to be integrated 
into non hepatocellular carcinoma tissue, but the 
DNA in individual hepatocellular carcinoma has 
been shown to be monoclonal in nature, thus 
supporting the observation that HBV DNA 
integration is a critical aetiologic factor in those 
tumours (81).  HBV DNA integration into the 
host genome has been found to occur at both 
critical and non-critical locations and appears to 
occur in a random manner with marked variation 
in the length and the components of the integrant 
HBV DNA (82).  The integration of HBV DNA 
into the host cell genome results in several 
mutagenic events that culminate in chromosomal 
instability and malignant transformation of 
affected cell (80).  Integration of HBV induces a 
host of genetic alterations within the host 
genome including chromosomal deletions, 
translocations and upregulation of genetic 
mechanisms responsible for maintaining cellular 
homeostasis and general genomic stability (68).   
 
A number of HBV genes and their products 
(proteins) have been implicated in HBV-related 
hepatocarcinogenesis.  These include HBx gene, 
pre-s2/s gene, and the HBV spliced protein.  Of 
these, HBx gene has been shown to be the most 
important and also the most commonly 
integrated gene – being present in over 90% of 
HBV-related cirrhosis and dysplasia; and in 70% 
of HBV related hepatocellular carcinoma (80). 
Integration of the HBx gene into host DNA 
results in transcriptional activation of several 
cellular genes associated with growth control 
(83), and promotion of host genetic instability 
through a variety of mechanisms that include 
compromise of host cell nucleotide excision 
repair (DNA repair) mechanisms, inactivation of 
p53 (a tumour suppressor gene) and disruption 
of p53-associated DNA repair pathways.  HBx 
also transactivates several cytoplasmic signaling 
pathways in ways that further compromise 
cellular proliferation and differentiation - with 
the balance tilted towards enhanced proliferation 
and decreased apoptosis (68). HBx has also been 
shown to be a factor in promoting TGF-beta 
mediated fibrosis, thus promoting development 
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of cirrhosis in HBV infected patients. Animal 
models studies also provide evidence supporting 
the role of HBx in hepatocarcinogenesis.  It has 
been shown for instance, that woodchucks 
animal models in which HBx gene is present and 
integrated into the host genome develop 
hepatocellular carcinoma within 3-4 years 
following infection; whereas, duck hepatitis B 
virus infection in which the virus lacks the HBx 
gene never results in the development of cancer 
in infected ducks (84).   
 
2:2:3 Hepatitis B Viral Hepatocarcinogenesis 
and Cirrhosis 
 
Although hepatitis B virus may cause 
hepatocellular carcinoma directly without 
cirrhosis, it appears that the high propensity of 
the virus to cause hepatocellular carcinoma is 
due to the virus’s ability to induce cirrhosis in the 
liver.  Between 70-80% of HBV related 
hepatocellular carcinoma occur in cirrhotic liver - 
with the risk of cirrhosis being greater in older 
patients (69,80,85). Cirrhosis irrespective of its 
aetiology, is known to be associated with 
increased risk for hepatocellular carcinoma.  80-
90% of all hepatocellular carcinomas develop in 
cirrhotic liver (86). Liver cirrhosis develops in 20-
30% of patients after 20-30 years of chronic 
infection and hepatocellular carcinoma  develops 
at an annual of 1-7% in HCV infected cirrhotic 
patients and 3-8% in HBV infected cirrhotic 
patients (68,87,88).  This may explain in part, the 
higher incidence of HBV associated 
hepatocellular carcinoma in HBV endemic 
regions (sub-Saharan Africa and East Asia). In 
those regions, HBV is acquired at birth or early in 
life (through maternal-infant transmission), with 
consequent high rate of lifelong chronic infection 
(that is often unabated) and eventual evolution of 
the disease into cirrhosis and hepatocellular 
carcinoma; compared with western populations 
where hepatitis B infection is usually acquired 
during adolescence or adulthood (commonly 
through sexual contact).   
 
Since HBV infection is the major aetiologic risk 
factor for hepatocellular carcinoma globally, the 
most effective way of preventing and controlling 
hepatocellular carcinoma secondary to HBV 
infection is to prevent HBV infection and so 
reduce the seroprevalence of HBV in the general 
population.  Use of HBV vaccination (large scale 
national programs of vaccination against of 
hepatitis B) in many countries has proven to be 
an effective way (cost effective and efficient way) 
of achieving this objective.  The resultant 
decrease in hepatitis B infection and HBV related 
cirrhosis has resulted in marked reduction in the 
incidence of childhood HBV related 
hepatocellular carcinoma and it is expected that 
this would also later transform to reduction in 
the incidence and prevalence of HBV related 
hepatocellular carcinoma as the vaccinated 
children populations grow into adulthood (69).  
Also, since high level of serum of HBV DNA has 
been shown to be associated with increased risk 
of hepatocellular carcinoma, aggressive and 
effective use of antiviral therapy of hepatitis B 
infection is another practicable way of preventing 
HBV related hepatocellular carcinoma (89).  
 
3. HEPATITIS C VIRUS HEPATOCELLULAR 
CARCINOMA  
 
HCV is an RNA virus and belongs to the 
Flaviviridae family.  It has an open reading frame 
that encodes a single polyprotein which is 
processed into both structural (core and 
envelope) and non-structural proteins.  Patients 
infected with HCV have 11.5 to 17 fold increased 
risk for developing hepatocellular carcinoma 
(90,91). 
 
In the host cells, HCV being an RNA virus is 
unable to integrate itself into the host genome. 
Therefore, the viral RNA genome is replicated 
and packaged into new viral particles in the 
cytoplasm of host cells through the combined 
machinery of viral and host proteases.  The 
associated translation of viral protein results in 
host responses that facilitate oncogenic 
(malignant) transformation of the host cells.  
HCV core protein has been shown to be the most 
important factor in HCV-induced 
hepatocarcinogenesis (68).  The envelope proteins 
(E1 and E2) appear to have synergistic effects in 
accelerating tumour development.  When treated 
with Diethylnitrosamine, transgenic mice 
expressing core protein, E1 and E2 envelope 
proteins develop tumours faster than mice 
expressing only core protein (92).  This recent 
finding confirms earlier reports that in transgenic 
mice, the presence of the complete HCV 
polyprotein enhances hepatocellular carcinoma 
development in a more efficient manner 
compared with the presence of structural 
proteins alone (93). In the absence of structural 
proteins, HCV non-structural proteins do not 
cause any known liver pathology (94).   
 
The exact molecular mechanism through which 
HCV induces hepatocarcinogenesis is yet to be 
fully understood.  HCV proteins induce 
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hepatocarcinogenesis through a combination of 
complex and sometimes overlapping molecular 
events that ultimately result in suppression of 
apoptosis, and enhancement of proliferation of 
the infected hepatocytes.  This is done mainly 
through modulation of p53 and p53 dependent 
pathways, such as those mediated by p21, p73 
and pRb; and results in derangement of cell cycle 
control mechanisms (68).  HCV core protein 
through Smad3 activation reverses TGF-Beta cell 
growth-suppressing effect to tumour-promoting 
responses in the infected cells (95).  In addition, 
by upregulating TGF-Beta, HCV core protein 
induces fibrogenesis, causing liver cirrhosis and 
therefore increasing the risk of hepatocellular 
carcinoma (96).   
 
HCV infection is also associated with steatosis 
and that has been shown to occur in as high as 
70% of patients with chronic HCV infection (97).  
Steatosis worsens fibrosis and accelerates the 
development of cirrhosis and is also an 
independent high risk factor for the development 
of hepatocellular carcinoma in HCV infected 
patients (98).  HCV induced steatohepatitis and 
fibrogenesis result from increased oxidative 
stress and lipid peroxidation.  These result in 
generation of radical oxidative species (ROS) and 
consequent oxidative DNA damage, increased 
chromosomal instability, chromosomal 
aberrations and eventually, oncogenic 
transformation of the host cell.   
 
Patients with chronic hepatitis infection often 
have elevated serum iron and increased hepatic 
iron deposition.  Free iron in hepatocytes 
cytoplasm results in increased oxidative stress 
and so enhances lipid peroxidation and also 
facilitates fibrogenesis and development of 
cirrhosis (99-101).  
 
In summary, chronic HCV infection is associated 
with three distinct pathologic events that are 
associated with increased risk of hepatocellular 
carcinoma, viz: steatosis, hepatocytic 
accumulation of iron and cirrhosis.   
 
4. HUMAN HERPES VIRUS 8 (KAPOSI’S 
SARCOMA-ASSOCIATED HERPES VIRUS) 
 
Kaposi’s sarcoma (KS), a multicentric tumour of 
endothelial cells was first described in 1872 by 
Moritz Kaposi as “idiopathic multiple pigmented 
sarcoma of skin” that affects elderly Jewish men 
of Ashkenazi origins and was later named 
Kaposi’s sarcoma (KS) by Koebner in 1895.  
During the 1940s through 1980, endemic KS was 
described in parts of Central and East Africa 
(Uganda, Malawi and Kenya) where it most 
commonly affects children and presents with 
disseminated lymphadenopathy, hence the 
designation lymphadenopathic KS (102,103).  In 
1969, the first case of KS occurring after an organ 
transplant was reported (104) and thereafter, it 
has been established in the literature that 
iatrogenic KS occurs in immunosuppressed 
individuals such as organ transplant patients 
105).  In 1981, report of KS epidemic affecting 
young homosexual men in the USA was the first 
indicator of a soon to-be-discovered HIV1 
infection pandemic (106-108). As of today, KS is 
the most common neoplasm in untreated HIV 
infected patients; and remains the most common 
AIDS-associated cancer in both developed and 
developing countries (109).  In the western 
world, it continues to be most prevalent among 
HIV-infected homosexual men; whereas, in 
Africa, due to sexual practices that may include 
multiple sexual partners in heterosexuals and 
bisexual individuals, HIV-related KS epidemic is 
common among both male and female genders 
(110). 
 
The incidence of KS in the general population is 1 
in 100,000, 1 in 20 in HIV-infected individuals 
and was as high as 1 in 3 in HIV-infected 
homosexual men before the introduction of 
highly active antiretroviral therapy (HAART) 
(111,112).  Due to lack of adequate or appropriate 
treatment of HIV infection, about 90% of all KS 
cases now occur in Sub-Saharan Africa and only 
about 12% of patients are alive five years after 
diagnosis (110,113,114).  In the developed 
countries, the advent and success of HAART led 
to a dramatic drop in the incidence and mortality 
of HIV-related KS (115,116)  
 
Since the 1950s, an infectious agent has been 
suspected to cause KS.  Herpes viral particles in 
tissue culture of KS lesional cells were 
demonstrated by electron microscopy in 1972 
(117). However, it was much later (in 1990) 
following the emergence of HIV/AIDS pandemic 
that an infectious agent was proposed as the 
etiologic factor for KS (112).  In 1994, a definite 
association was established between a new 
human gamma herpes virus and KS through 
isolation and characterization of DNA fragments 
obtained from KS tissue biopsy specimens. In 
that study, the new herpes virus DNA sequences 
were isolated from more than 90% of KS tissues 
and 15% of non-KS tissues of AIDS patients and 
in none of the tissue samples from non-AIDS 
patients (118).  The new virus was named 
Kaposi’s Sarcoma-associated Herpes Virus 
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(KSHV - now also known as Human Herpes 
Virus 8 {HHV8}). HHV8  latency associated 
nuclear antigen  (LANA) is expressed in all cells 
infected by the virus and irrespective of the 
underlying clinical condition, over 95% of KS 
have been found to be infected with this virus  
(119). The immunohistochemical detection of the 
viral latency protein 
(LANA) has become a 
useful tool in the 
histopathologic diagnosis of the tumour using 
light microscopy (120,121). The strong association 
of KS epidemic with the HIV infection pandemic 
eventually resulted in the identification of KS as 






A. Kaposi’s sarcoma with spindle cell proliferation of endothelial cells. 
B. Positive immunohistochemical staining for HHV8 in the nuclei of the tumour cells.  
 
Iatrogenic KS (also known as post-transplant KS) 
is immunosuppression-associated KS that occurs 
in transplant patients who receive solid organs 
such as kidney, pancreas and heart; and it is most 
common in renal transplant patients (123).  In 
this group of patients, long-term 
immunosuppression which is essential for 
preventing allograft rejection creates a 
microenvironment that is conducive for KSHV-
induced malignant transformation.  Fortunately, 
this form of KS usually resolves with withdrawal 
or reduction of the immunosuppressive therapy.  
 
In addition to KS, two highly aggressive and 
rapidly fatal non-Hodgkin’s B-cell lymphomas 
have also been associated with KSHV.  These are 
(1) primary effusion lymphoma (PEL) – a tumour 
that is also very common in HIV-infected 
patients with AIDS (124) and (2) plasmablastic 
lymphoma arising in patients with multicentric 
Castleman’s disease, especially in those who are 
also HIV positive (125,126). 
 
Oncogenetic transformation of endothelial cells 
and infected B lymphocytes by KSHV occurs 
through a complex multistep process that may 
result in genomic chromosomal instability, 
alternation of cell cycle and programmed cell 
death regulatory genes, increase in cell 
proliferation and long-term survival, and up-
regulation of cells’ invasive properties (103).  
KSHV like other herpesviruses has a double 
stranded DNA genome and possesses a long 
unique region in which 15 unique open reading 
frames (ORFs) are located.  These are designated 
sequentially K1 through K15 based on their 
relative locations in the KSHV genome and are 
involved in signal transduction, cell cycle 
regulation, inhibitions of apoptosis and immune 
modulation.  The virus also possesses some 
microRNAs (a total of 12 discovered so far); they  
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play critical roles in KSHV pathogenesis (103).  
KSHV has a two-phased life cycle that is typical 
for herpesviruses.  The lytic phase characterized 
by active replication of linear viral genomes and 
production of immediate early (α), early (β) and 
late (γ) transcripts and an episomal latent phase 
during which the virus exist in the host cell as 
circularized extrachromosomal viral genome – a 
state in which no infectious or functional viral 
particles are produced.  This state of latency is 
established and maintained principally by the 
latency nuclear antigen (LANA) (127-129).  
LANA and other viral proteins interact with p53 
and other cell cycle regulatory proteins and as a 
result derange a host of cellular pathways 
involved in cell proliferation, programmed cell 
death and tumourigenesis (103,130). 
 
 
5. HUMAN PAPILLOMA VIRUS 
 
5:1 HPV and Human Cancers - Historical 
Account 
 
A probable relationship between cervical cancer 
and sexually transmitted agents was first noted 
in 1842 by Rigoni-Stern who reported a high 
frequency of cervical cancer in married women, 
widows, and prostitutes; but rare in virgins and 
nuns (131).  With the advent of better 
bacteriology and virology techniques in the latter 
part of the 20th century, in the late 1960’s and 
early 1970’s, a number of investigators reported 
Herpes simplex virus type 2 as the likely 
causative agent for sexual disease - related 
cervical cancer.  But large scale prospective 
studies exonerated Herpes simplex type 2 virus 
as the likely candidate (132). 
 
In the late 1970s and early 1980s, Vonka et al 
(133,134) conducted a large prospective study in 
attempts to establish a relationship between 
Herpes simplex type 2 virus and its causative 
role in cervical neoplasia.  In a study conducted 
over 8 years (1975 to 1983), 10,683 women were 
enrolled and 10,389 had complete set of data.  In 
the subset of women with moderate to severe 
squamous dysplasia, squamous cell carcinoma in 
situ and invasive squamous cell carcinoma either 
at enrollment or during the follow-up period, the 
prevalence of Herpes simplex type 2 virus 




A. Hematoxylin and Eosin-stained tissue section micrograph of HPV-associated 
squamous cell carcinoma of the oropharyngeal. 
B. In-situ hybridization showing presence of HPV in the nuclei of the tumour 




appropriately matched by age, age at first 
intercourse, number of sexual partners, smoking 
habits and clinical integrity of the cervical ectopic 
epithelium (ectocervix) and the transformation 
zone. That landmark report was followed by 
intense investigation and search for the culprit 
pathogenic agent and eventually led to the 
identification and confirmation of Human 
Papilloma Virus (HPV) as the causative agent. In 
the 1970’s, there were anecdotal reports of 
association between HPV induced genital warts 
(Condyloma acuminata) and cervical cancer.  In 
1982, the presence of HPV DNA in invasive 
squamous cell carcinoma was reported (135) and 
soon confirmed by additional reports in the 
following year.  That was followed by a burst of 
additional confirmatory epidemiological, 
histopathologic and molecular data in the years 
that follow (136,137).  Today, there are more than 
200 known types and 20% of them known to 
cause human infections. 
 
5:2 HPV and Anogenital/Uterine Cervical 
Cancers 
 
Cervical cancer is the second most common 
cancer in women worldwide with about 500,000 
new cases and 274,000 cervical cancer deaths 
occurring each year (138).  A disproportionately 
high percentage of these new cancer cases and 
deaths (about 80%) occur in developing countries 
(138).  There is an abundance of epidemiological 
and experimental data that show HPVs have 
causative roles in genital as well as extragenital 
mucocutaneous squamous cell carcinomas.  
HPVs are the most sexually transmitted viruses, 
the most prevalent viruses implicated in causing 
cancer in human populations and second only to 
tobacco usage as most important risk factors for 
developing cancer in human beings (139).  
 
HPV has now been shown to be the causative 
agent in almost 100% of cervical cancer, and is 
also responsible for about 50% of vulva 
squamous cell carcinoma (140), 30 to 50% of 
penile carcinomas (141-143), 60 to 90% of vaginal 
carcinomas (140,144) and also with a similar 
percentage for anal and perineal cancers (145).  A 
large study of cervical cancer material collected 
from patients in 22 countries all over the world 
revealed HPV genome in 99.7% of cases (144).   
  
A recent Medline review of 1,824 cases from 37 
studies using PCR or hybrid capture for HPV 
detection in anal squamous dysplasia and 
invasive carcinoma shows the prevalence of HPV 
16 and 18 to be 90% (n=832) in squamous 
dysplasia and about 70% in invasive carcinoma 
(n=992); similar to the prevalence observed in 
invasive cervical cancer (146).  A similar review 
of HPV distribution in vulvar and vaginal 
cancers show an HPV prevalence of 40% in 
invasive vulvar carcinoma (n=1379) and about 
80% in vulvar squamous dysplasia; and a much 
higher rate in the vaginal cancers and 
premalignant (dysplastic) vagina epithelium – 
65% and greater than 90% respectively (147). 
 
Meta–analysis of pooled data on HPV type 
distribution and prevalence between 1990 and 
2010 and including 243 studies with a total of 
30,848 cases of invasive cervical cancer showed a 
steady increase from 85.9% in the 1990s to 92.9% 
in studies published between 2006 and 2010.  The 
prevalence of HPV 16 and/or 18 was 82% in 
Western/Central Asia and 68% in Eastern Asia 
(148). In recent study of uterine cervix squamous 
dysplasia (premalignant lesions that predate 
HPV induced invasive carcinoma), HPV was 
detected in 98.4% of women (n=643) with more 
than half of them (52.5%) infected with more than 
one HPV serotype; and HPV 16 was the most 
commonly detected type.  Other HPV types 
detected include HPV 31, 33, 52, 18 and 51 (149).  
A multisite study of HPV types specific 
prevalence in women with cervical cancer and 
premalignant intraepithelial changes in the cervix 
in England and involving 6,234  women showed 
the prevalence of HPV 16 and/or 18 to be 76% in 
squamous cell carcinomas, 82% in 
adeno/adenosquamous carcinoma and 63% and 
91% respectively in severe cervical squamous 





5:3 HPV and Cancer of the Head and Neck 
Region 
The first evidence of HPV involvement as 
causative agents of oropharyngeal cancers was 
first reported in 1983 by Syrjanen et al (156) when 
they showed the presence of positive 
immunoperoxidase staining for HPV in oral 
epithelial hyperplasia and squamous cell 
papillomas.  That was followed by a report of 
specific HPV types in cancer of the tongue and 
oropharyngeal region (157).  Subsequent studies 
have since confirmed the association of HPV with 
cancer of the head and neck regions especially 
that of the oropharyngeal region with rate of 
positivity varying between 25 to 60% (132,158).  It 
is now conservatively estimated between 25 to 
30% of oropharyngeal cancers are caused by HPV 
and that the virus does have some aetiological 
role in these tumours (132).  There is increasing 
incidence of oropharyngeal, tongue base and 
tonsillar cancer in the young men and women in 
the United States and evidence abounds that 
HPV infection is the underlying aetiological 
factor (159). 
 
In a multicenter case control study involving 9 
countries, it was shown that HPV is involved in 
significant proportion of oropharyngeal cancers 
and in a smaller group of squamous carcinoma of 
the oral cavity.  Also in that study, it was found 
that 70% of the tumours contain HPV DNA with 
HPV 16 as the most frequently observed; a 
scenario that is similar to that observed in HPV-
related genital cancers (160).  Studies using very 
reliable techniques (quantitative PCR and in-situ 
hybridization) have shown that HPV occur in 
only a small proportion of oral cavity squamous 
cell carcinoma and in up to 60% of oropharyngeal 
tumours (161,162).  Kreimer, AR et al (163) 
reviewed published studies that employ PCR 
based method to detect and genotype HPV in 
order to describe the prevalence and HPV type 
distribution by anatomic cancer sites and 
geographic location, as possible source of 
variability. With a total of   5,046 cases of 
squamous cell carcinoma from 60 eligible studies 
from 26 countries, the overall HPV prevalence in 
head and neck cancer was reported as 25.9% and 
HPV prevalence was significantly higher in 
oropharyngeal squamous cell carcinoma (35.6% 
compared to 23.5% in oral squamous cell 
carcinoma and 24.0% in laryngeal squamous cell 
carcinoma).  HPV 16 accounted for the majority 
of HPV positive oropharyngeal carcinoma 
(86.7%) compared with 68.2% and 69.2% in HPV 
positive oral and HPV associated laryngeal 
squamous cell carcinoma.  HPV 18 which is the 
second most common detected high risk type 
was found in only very small number of cases.  
HPV 18 detection rate was 8%, 3.9% in oral and 
laryngeal cancers and only 1% oropharyngeal 
cancers.  HPV prevalence in oral squamous 
carcinoma was found to be similar in Europe and 
North America (16 and 16.1% respectively) but 
was significantly greater in Asia (33%).  
However, with oropharyngeal carcinoma, HPV 
prevalence was significantly higher in North 
America (47%) compared with Europe (28.2%).  
In the cases from Asia, the HPV prevalence rate 
for oropharyngeal carcinoma was rather high 
(46.3%) but the number of cases studied was very 
small (n=54). Thus in all, HPV prevalence in oral 
squamous cell carcinoma from Asia was 
considerably higher than other geographic 
locations and HPV prevalence was higher in 
oropharyngeal squamous cell carcinoma from 
North America and Asia compared with Europe 
(162).  However, in a multicontinent study 
conducted by IARC, HPV prevalence did not 
differ significantly among Europe, North and 
South America, Asia and Africa (162,163).    
 
Squamous cell carcinoma of the head and neck 
region is traditionally believed and has been 
shown to be related to environmental factors 
such as tobacco use and alcohol abuse.  However, 
it has also been shown that a small but significant 
proportion (15-20%) of this cancer occur in 
patients without these traditional risk factors 
(164).  This is further confirmed by the fact that 
the incidence of oropharyngeal cancer is 
increasing and tends to occur more in young 
male patients while the incidence of tobacco use 
and over all incidence of squamous carcinoma of 
the head and neck region are decreasing 
(158,165).  
 
Similar to what occurs with genital HPV related 
malignancies, HPV positive head and neck 
squamous carcinoma is related to sexual history. 
The risk factors include increasing number of 
oral and vaginal sexual partners, history of 
genital warts, and younger age at first 
intercourse (161,166,167). Also, Gillison et al (167) 
reported increasing association of HPV 16 
positive head and neck cancer with increased use 
of marijuana. While the means by which HPV is 
transmitted to the upper airways is unclear, it 
does appear to be related to sexual activity and 
sexual behaviors – since  oral HPV infection is 
rare in newborn babies of infected mothers and 
in children prior to sexual activity (168,169).  
Additional sexual behaviours strongly associated 
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with high risk HPV positive tumour include 
history of oral sex and oral-anal contact (170,171).  
There is also an increase in individuals with a 
history of HPV associated anogenital cancers and 
in husband of women with HPV related in-situ 
squamous cell carcinoma and invasive cancer 
(164). Patient with anogenital cancers have a 4.3 
fold increase risk of tonsillar cancers and there 
are remarkable histopathological and molecular 
biological similarities between HPV tumours at 
these two sites (172).   
 
HPV-associated head and neck cancer have 
characteristically distinct features that 
distinguish them from the non HPV-related head 
and neck cancers.  HPV-related squamous cell 
carcinoma of head and neck tends to be more 
common in the oropharyngeal region, and affects 
men and women equally; unlike tobacco 
associated cancers that are more frequent in men.  
HPV-associated cancers patients also tend to be 
non smokers, non drinkers, and tend to be 
younger (164). HPV positive head and neck 
cancer also have distinct histologic appearance.  
They tend to be more poorly differentiated, non 
Keratinizing and have basaloid appearance. 
However, other patterns such as papillary 
squamous cell carcinoma have also been 
described (158).  
 
5:4 HPV and Carcinogenesis 
 
Human papilloma virus (HPV) is a double 
stranded DNA virus with all putative open 
reading frames (ORFs) on one DNA strand, and 
the presumably non coding strand containing 
short ORFs which are conserved regardless of 
localization and composition (164). The putative 
genes consist of early genes (E1-E8) which are 
expressed shortly after infection and prior to 
onset of DNA replication, and late genes (L1 & 
L2) which code for structural proteins of viral 
capsids and are activated late during the final 
stages of the virus circle.   
 
HPVs are epitheliotropic viruses that cause 
mucocutaneous infections. Currently, more than 
200 types are known with about 40 of them 
having been described to infect human mucosa 
and the individual types have varying 
predilections for different epithelial surfaces and 
different oncogenic potentials (173).  Based on 
their oncogenic potential (ability to cause cancer), 
they are divided into low risk and high risk types 
(174). With infection of epithelial cells through 
abrasions or micro trauma, the virus integrates 
into the epithelial cells and cause abnormal 
growth of the cells.  The high risk HPV types by 
virtue of their E7 proteins integrate themselves 
into the genome of the host epithelial cells, 
immortalize the cells infected and cause 
dysregulation of the host cells’ cell cycle and 
apoptosis regulatory proteins and pathways.  The 
high risk HPV types include types 16, 18, 31 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 73 (175).  
HPV types 16 and 18 are responsible for 
approximately 70% of all cervical cancers and are 
also the culprits in the squamous carcinoma of 
the ano-genital region including vulva, anal, and 
penile cancers (164).  They have also been shown 
to be the main types involved in HPV related 
head and neck squamous cell carcinomas (176).  
 
HPV infects the basal cells and the virus early 
genes E6 and E7 (both of which encode 
oncoproteins) integrate into the host cell genome. 
In the actively dividing basal epithelial cells, 
virus maturation parallels that of the infected 
host cells as they mature and differentiate into 
more mature cells.   Hence, the early viral genes 
are found in basal cells and late genes are in the 
more superficial keratinizing epithelial layer.  
The E6 protein of the high risk HPV binds to and 
induces degradation of the tumour suppressor 
protein p53 (through an ubiquitin- mediated 
process); resulting in dysregulation of the innate 
cellular tumour supressor process.  The E7 
protein of high risk HPV types on the other hand, 
causes destruction of phosphorylated 
retinoblastoma proteins mediated transcriptional 
repression of genes that are involved in 
regulation of the cell cycle.  The combined 
subcellular (molecular) activities of E6 and E7 
proteins of high risk HPV types, results in loss of 
control of the cell cycle and apoptosis control 
mechanisms. Thus the infected cells become 
immortalized and acquire oncogenic potentials 
that enable them to go into uncontrolled cellular 
proliferation and tumour formation (177-183).  
Although integration of the E6 and E7 proteins 
into the host genome is believed to be central to 
HPV-mediated carcinogenesis with the 
integration of HPV DNA into the host genome as 
the key event, recent studies have shown that 
transcription of HPV-16E6-E7 mRNA is not 
necessarily dependent on DNA integration - as 
the viral DNA which is predominately in 
episomal (unintegrated) form  takes part in the 
carcinogenesis process (184,185). E6 through 
binding of p53 and inducing its degradation, 
impairs host cell apoptosis and causes instability 
of the host genome (increased predisposition of 
the genome to mutations and changes that 
supports cellular proliferation). E6 binding also 
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inactivates telomerase (enzyme responsible for 
maintaining telomeric DNA stability).  E7 
binding to phosphorylated retinoblastoma 
proteins and related proteins, results in 
upregulation of transcriptional factors that 
activates or turns on genes that regulate cell 
proliferation.  The down regulation of 
phosphorylated retinoblastoma protein by E7 
also result in the upregulation of p16 which is 
now used as a surrogate marker for HPV 
infection in squamous cell dysplasia – the 
histopathologic manifestation of the 
premalignant transformation of  HPV infected 
cells (186-188) 
 
Fortunately, majority of HPV infection of 
epithelial cells is self-liming - cleared by the 
host’s humoral and cell mediated immune 
responses through poorly understood 
mechanisms (189). However, infection caused by 
high risk HPV types results in subversion and 
evasion of the host’s virus clearing immune 
mechanism and persistent infection that may 
culminate in malignant transformation of 
infected host cells.  It appears that there are other 
factors in play to initiate the process of 
carcinogenesis and for the progression through 
low grade dysplasia to high grade dysplasia and 
ultimately invasive squamous cell carcinoma.  
This is supported by report that high risk HPV 
serotypes are three fold more frequently 
encountered in patients with malignant lesions 
than in those with benign or precancerous lesions 
(190).  The precursor lesions of infection by high 
risk HPV types persist longer and also progress 
more quickly in individuals infected with these 
high risk oncogenic viruses compared with those 
infected by the low risk non oncogenic HPV 
types (191,192).  Hence, the need for typing the 
HPV detected in individuals that undergo HPV 
screening. In so doing, individuals at risk would 
be followed with the appropriate aggressive 
management scheme; while those infected with 
less aggressive types are spared unnecessary 
aggressive management.        
 
Although HPV DNA integration into the host 
genome results in genomic instability, it is 
noteworthy that HPV positive cancers tend to 
have significantly lower levels of chromosomal 
mutations and loss compared to the HPV 
negative tumours at the same sites (191,194).  
Presence and high levels of active HPV infection 
as demonstrated by elevated levels of p16 in 
tumour cells, have been shown to be associated 
with higher survivor rates of 79% five year 
survival compared with 20% five year survival in 
individuals with HPV negative tumours (195). 
This improved survival in HPV related 
squamous cell carcinoma compared with HPV 
negative tumours has since been confirmed by 
other studies (196,197). HPV associated head and 
neck squamous cell carcinoma are more 
responsive to treatment - being more 
radiosensitive and have better survivor rates 
compared to their non HPV-related counterparts.   
Also, HPV related tumours have been shown to 
have higher response rate to induction 
chemotherapy and chemoradiation (198). The 
higher response to chemotherapy and radiation 
by HPV associated tumour has been attributed to 
improved apoptotic response facilitated by the 
presence of unmutated p53 and absence of  other 
chromosomal abnormalities in HPV related 
cancers; in contrast to p53 mutation and other 
chromosomal abnormalities that tend to occur in 
HPV negative tumours. Also in HPV negative 
tumours, the inducing agents such as tobacco 
and alcohol are known to cause p53 mutation 
and field cancerization – processes that result in 
subcellular genetic events that make the tumour 
cells in those cases to be less radiosensitive and 
also predispose those individuals to development 
of a second primary cancer (176).  Similar to what 
obtains with HPV associated head and neck 
tumours, HPV positive vulva and penile 
carcinoma also seem to have better prognosis and 
more favorable therapeutic response in 
comparison with HPV negative tumours (163).  
 
6. HUMAN T- CELL LYMPHOTROPHIC 
VIRUS 1 
 
6:1 Human T-cell Lymphotrophic Virus 
Subtypes 
 
Human T-cell lymphotrophic virus (HLTV) 1 was 
the first retrovirus to be associated with human 
disease. It was first isolated and identified in 1980 
by Poresz, et al from the T-cells of a patient with 
cutaneous lymphoma (199).  Soon thereafter, 
Human T-cell lymphotrophic virus type 2 
(HLTV2) was isolated from a patient with hairy-
cell leukemia (200). Both HLTV1 and HLTV2 
infect helper T-cells and have similar genomic 
structure with 66% nucleotide sequence 
homology in their genome; hence the serologic 
cross-reactivity between the two.   Recently (in 
2005), two additional related viruses – HLTV-3 
and HTLV-4 were reported in Central Africa 
(201). However, only HLTV-1 has been shown to 
have etiological association with a number of 
diseases (202). There are six subtypes of HLTV-1 
(subtypes A-F); but they all appear to have 
similar pathogenicity (203). 
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6:2 HLTV-1 Infections.  
 
It is estimated that there are about 20 million 
HLTV-1 infected individuals in the world with 
the highest prevalence rates in southwestern 
Japan, sub-Sahara Africa, Caribbean Islands, 
South America, Papa New Guinea, and Iran 
(204).  The most common mode of transmission is 
mother-to-child vertical transmission - mostly 
through breast feeding (205,206) and that has 
been shown to be directly proportional to the 
duration of breast feeding and the provirus load 
in the milk (207-210).  Other modes of 
transmission include sexual contact (211), blood 
transfusion (212) and sharing of contaminated 
needles (206).  Fortunately, the overwhelming 
majority (about 90%) of individuals infected by 
HLTV-1 are asymptomatic throughout their 
lifetime (213).  HLTV-1 was originally associated 
with Adult T-cell leukemia/lymphoma (ATLL), 
but it has also been associated with the following 
non neoplastic diseases: uveitis, arthropathy, 
polymyositis, thyroiditis, Sjögren’s syndrome, 
inflammatory dermatopathic disease conditions, 
myelopathy and tropical spastic paraparesis 
(213,214).  Some of the inflammatory 
dermatologic conditions associated with HLTV-1 
occur as part of the disease entity called infective 
dermatitis associated with HLTV1 – a severe and 
recurrent eczema that is characterized by 
occurrence in childhood, chronic rhinorrhea and 
chronic relapsing dermatitis. There is associated 
infection of the skin and nasal vestibules by non-
virulent Staphylococcus aureus or Beta-hemolytic 
streptococcus; therefore the dermatitis responds 
promptly to antibiotic therapy but also recurs 
promptly on withdrawal of the antibiotic 
treatment. (215-217).  HLTV-1 infected patients 
are also known to be more predisposed to 
developing other skin conditions including 
xerosis, acquired ichthyosis, seborrheic 
dermatitis, non infectious erythematous 
dermatitis and infectious skin diseases 
(dermatophytosis, scabies, verruca vulgaris and 
bacterial infections) (218-221).  The presence of 
chronic (recurrent and sometimes refractory) skin 
conditions in HLTV-1 infected patients is thought 
to result from immune dysregulation and is 
associated with protracted high levels of 
cytokines which support the development of 
lymphoproliferative disorder.  Therefore, the 
presence HLTV-1 associated skin conditions is an 
indicator for increased risk for developing 





6:3 HLTV1 and ATLL (Pathogenesis) 
 
Following infection of a T-cell, the proviral DNA 
(generated from the viral RNA), integrates into  
the host genome and spreads only as the infected  
cells divide.  Two viral accessory genes tax and 
HTLV-I b-ZIP factor (HBZ) enhance infectivity 
by inducing cell proliferation, modulate 
programmed cell death and induce a series of 
processes that support cellular transformation 
and leukemogenesis (227,228).  HLTV-1 infection 
of T-lymphocytes results in T-cell activation and 
a hyperactive immune response that is 
characterized by exaggerated type 1 (Th1) 
immune response and spontaneous 
lymphoproliferation with increase in CD4+ 
counts, CD8+ counts and CD4+/CD8+  ratio 
(215,216,229).  B-cell activity is also markedly 
increased resulting in elevation of Ig A, Ig D, Ig 
E, and Ig G levels (215,216).  In the infected cells, 
the HLTV-1 protein tax also transactivates genes 
responsible for production of proinflammatory 
Th1 and Th2 cytokine such as tumour necrosis 
factor-alpha (TNF α), interferon-gamma (1FN-γ), 
interleukin 1, interleukin 5 and interleukin 6 
(214,217,230,231). 
 
In HLTV-1 carriers, elevated pro-viral load has 
been shown to strongly predispose such infected 
patients to the development of ATLL (232-234) 
and patients with HLTV-1 associated 
inflammatory skin conditions tend to have high 
pro-viral load.  In addition, associated bacterial 
infections results in synergistic stimulation of T-
lymphocytes by the bacterial antigens; further 
worsening exaggeration of the Th1 immune 
response and associated T-cell proliferation.  
Eventually, malignant transformation ensues, 
with the emergence of clones of T-cells that 
undergo uncontrolled proliferation (214). 
 
ATLL is an aggressive malignant 
lymphoproliferative disorder with heterogeneous 
clinical presentation.  There are four subtypes, 
viz; smoldering, chronic, lymphoma and acute 
types. The lymphoma and acute forms are more 
aggressive and have worse prognosis with less 
than 1 year survival after diagnosis (202,213).  
The incidence of ATLL in HLTV-1-infected is 
estimated to be less than 5% (235) and occurs 
almost exclusively in individuals who acquire the 
infection with vertical transmission through 
breast feeding (202,236).  ATLL usually occur two 
to three decades after the onset of HLTV-1 
infection. As a result, ATLL is generally reported 




ATLL has variable histopathologic appearances with 
features similar to those observed in other non HLTV-1 
related lymphoproliferative disorders.  Therefore, the 
diagnosis of ATLL is based on criteria that include positive 
HLTV-1 serology; the presence of hypercalcemia, detection 
of HTLV-1 pro-viral DNA is tumour cells (in lymphoma 
type) and the presence of abnormal T-cells in the peripheral 
blood (including flower cells) in the leukemic subtypes (202).  
The flower cells have characteristic polylobulated nuclei and 
are pathognomonic of ATLL. They are more commonly seen 
in acute ATLL - and can be readily identified with Giemsa or 
Wright staining of a blood smear – an attribute that allows 
for a quick and reliable diagnosis of acute ATLL – even in 
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